-
European Review For Medical and... Dec 2020This study aims to uncover the differential expression of circRNA_100395 in breast carcinoma specimens, and its regulatory effect on cancer cell phenotypes. The role of...
OBJECTIVE
This study aims to uncover the differential expression of circRNA_100395 in breast carcinoma specimens, and its regulatory effect on cancer cell phenotypes. The role of circRNA_100395 in affecting breast carcinoma progression and the molecular mechanism are explored as well.
PATIENTS AND METHODS
CircRNA_100395 expressions in breast carcinoma and paracancerous tissues were detected. The influence of circRNA_100395 level on clinical indicators of breast carcinoma patients was analyzed. In vitro regulations of circRNA_100395 on phenotypes of breast carcinoma cells were examined by CCK-8, colony formation, and transwell assay. The interaction between circRNA_100395 and MAPK6 was confirmed by Dual-Luciferase reporter assay and rescue assays.
RESULTS
CircRNA_100395 was downregulated in breast carcinoma tissues and cell lines. Its level was negatively correlated to tumor staging and tumor size of breast carcinoma. Overexpression of circRNA_100395 in SKBR3 and MDA-MB-231 cells weakened proliferative and migratory abilities. MAPK6 was the target gene of circRNA_100395. Overexpression of MAPK6 reversed the anti-cancer effect of circRNA_100395 on breast carcinoma.
CONCLUSIONS
CircRNA_100395 serves as an anti-cancer gene in breast carcinoma progression by targeting MAPK6, and its level is negatively correlated to tumor staging and tumor size of breast carcinoma. CircRNA_100395 can be utilized as a potential biomarker and therapeutic target of breast carcinoma.
Topics: Breast Neoplasms; Cell Proliferation; Cells, Cultured; Female; Humans; Middle Aged; Mitogen-Activated Protein Kinase 6; RNA, Circular
PubMed: 33336740
DOI: 10.26355/eurrev_202012_24012 -
Radiology and Oncology Feb 2020Background Metastatic progression of breast cancer is still a challenge in clinical oncology. Therefore, an elucidation how carcinoma cells belonging to different breast...
Background Metastatic progression of breast cancer is still a challenge in clinical oncology. Therefore, an elucidation how carcinoma cells belonging to different breast cancer subtypes realize their metastatic capacities is needed. The aim of this study was to elucidate a similarity of activated molecular pathways underlying an enhancement of invasiveness of carcinoma cells belonging to different breast carcinoma subtypes. Materials and methods In order to reach this aim, parental and invasive (INV) MDA-MB-231 (triple-negative), T47D (hormone receptor-positive), and Au565 (Her2-positive) breast carcinoma cells were used and their molecular phenotypes were compared using a proteomic approach. Results Independently from breast cancer subtypes, INV cells have demonstrated fibroblast-like morphology accompanied by enhancement of invasive and migratory capacities, increased expression of cancer stem cell markers, and delayed tumor growth in in vivo animal models. However, the global proteomic analysis has highlighted that INV cells were different in protein expressions from the parental cells, and Her2-positive Au565-INV cells showed the most pronounced molecular differences compared to the triple-negative MDA-MB-231-INV and hormone receptor-positive T47D-INV cells. Although Au565-INV breast carcinoma cells possessed the highest number of deregulated proteins, they had the lowest overlapping in proteins commonly expressed in MDA-MB-231-INV and T47D-INV cells. Conclusions We can conclude that hormone receptor-positive cells with increased invasiveness acquire the molecular characteristics of triple-negative breast cancer cells, whereas Her2-positive INV cells specifically changed their own molecular phenotype with very limited partaking in the involved pathways found in the MDA-MB-231-INV and T47D-INV cells. Since hormone receptor-positive invasive cells share their molecular properties with triple-negative breast cancer cells, we assume that these types of metastatic disease can be treated rather equally with an option to add anti-hormonal agents. In contrast, Her2-positive metastasis should be carefully evaluated for more effective therapeutic approaches which are distinct from the triple-negative and hormone-positive metastatic breast cancers.
Topics: Animals; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Phenotype; Proteomics; Receptor, ErbB-2; Triple Negative Breast Neoplasms
PubMed: 32061169
DOI: 10.2478/raon-2020-0007 -
Asian Journal of Surgery Dec 2022Patients with metastatic lobular breast carcinoma constitute a heterogeneous group with distinguishing features. Our aim was to describe the features and survival of...
PURPOSE
Patients with metastatic lobular breast carcinoma constitute a heterogeneous group with distinguishing features. Our aim was to describe the features and survival of them, and further subdivide them into subcategories for prognostic stratification and treatment planning.
PATIENTS AND METHODS
Patients with de novo metastatic breast cancer from 2010 to 2018 were identified using the SEER database. Multivariate logistic regression analysis was conducted to calculate odds ratios. The within-pair difference was minimized by propensity score matching. Multiple comparisons based on Cox proportional hazards model were performed to investigate the interactions of M1 subcategory and treatment modality on survival.
RESULTS
A total of 1,675 patients with de novo metastatic lobular breast carcinoma were identified, they were more likely to have HR+/HER2- subtype, low histologic grade, low T/N stage, fewer metastatic sites, but worse prognosis compared with patients with metastatic ductular breast carcinoma. The M1 stage was subdivided into 3 subcategories with significantly different prognoses. The benefits of primary tumor surgery were more pronounced in M1a/b disease, whereas the benefits of chemotherapy increased with the progression of metastatic disease.
CONCLUSION
Patients with metastatic lobular breast carcinoma have unique clinicopathological characteristics and metastatic patterns. M1 subcategory assists prognosis stratification and treatment planning for such patients.
Topics: Humans; Female; Carcinoma, Lobular; Prognosis; Breast Neoplasms; Proportional Hazards Models; Neoplasm Staging
PubMed: 35012851
DOI: 10.1016/j.asjsur.2021.12.036 -
Archives of Pathology & Laboratory... Dec 2011Secretory carcinoma is a rare but distinct subtype of breast carcinoma, with characteristic histomorphology and generally favorable prognosis. Although it was originally... (Review)
Review
Secretory carcinoma is a rare but distinct subtype of breast carcinoma, with characteristic histomorphology and generally favorable prognosis. Although it was originally described as a juvenile breast carcinoma, occurring in young children, most cases have been reported in adults of both sexes. As the name implies, the characteristic histomorphology is the presence of a large amount of intracellular and extracellular, eosinophilic secretion material that stains positive for periodic acid-Schiff. Most tumors stain positive for S100 and negative for estrogen receptor, progesterone receptor, and ERBB2 (formerly HER2/neu) (ie, triple negative). In addition, some secretory carcinomas demonstrate a basal-like immunoprofile. Recent studies have shown the characteristic molecular feature: a balanced translocation t(12;15), resulting in an ETS variant 6-neurotrophic tyrosine kinase receptor type 3 (ETV6-NTRK3) fusion gene encoding a chimeric tyrosine kinase. Although rare events of axillary lymph node or distant metastases have been documented, the prognosis is generally excellent. The methods of surgical treatment and the role of adjuvant therapy, particularly for young patients, remain controversial.
Topics: Adult; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Child; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Diagnosis, Differential; Female; Humans; Immunohistochemistry; Male; Oncogene Proteins, Fusion; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Translocation, Genetic
PubMed: 22129193
DOI: 10.5858/arpa.2010-0351-RS -
Cancer Epidemiology, Biomarkers &... Jan 2020Prior studies evaluating psychotropic medications in relation to breast cancer risk are inconsistent and have not separately evaluated invasive and disease. (Clinical Trial)
Clinical Trial Observational Study
BACKGROUND
Prior studies evaluating psychotropic medications in relation to breast cancer risk are inconsistent and have not separately evaluated invasive and disease.
METHODS
We estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association of psychotropic medication use (any, typical antipsychotics, atypical antipsychotics, and lithium) with invasive and breast cancer risk among Women's Health Initiative participants ( = 155,737).
RESULTS
Prevalence of psychotropic medication use was low ( = 642; 0.4%). During an average 14.8 (SD, 6.5) years of follow-up, 10,067 invasive and 2,285 breast tissues were diagnosed. Any psychotropic medication use was not associated with invasive breast cancer risk compared with nonusers (HR, 0.82; 95% CI, 0.57-1.18). breast cancer risk was higher among "typical" antipsychotic medication users compared with nonusers (HR, 2.05; 95% CI, 0.97-4.30).
CONCLUSIONS
These findings do not support an association of psychotropic medication use with invasive breast cancer risk. The possible elevation in breast cancer risk associated with "typical" antipsychotics could not be explained by differences in screening mammography utilization and merits further study.
IMPACT
Our findings contribute to knowledge of the safety profile of psychotropic medications and may be useful to clinicians and patients considering use of these medications.
Topics: Aged; Breast; Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Follow-Up Studies; Humans; Mammography; Middle Aged; Postmenopause; Proportional Hazards Models; Psychotropic Drugs; Risk Factors; United States
PubMed: 31685559
DOI: 10.1158/1055-9965.EPI-19-0776 -
Cancer Jan 2003Breast cancer mortality rates are higher among African-American women compared with white American women, yet little is known regarding ethnicity-related variation in... (Review)
Review
BACKGROUND
Breast cancer mortality rates are higher among African-American women compared with white American women, yet little is known regarding ethnicity-related variation in patterns of primary surgical treatment, locoregional recurrence rates, and response to induction chemotherapy.
METHODS
The available literature was reviewed to evaluate outcome from breast-conservation therapy in African-American women and response rates to systemic therapy.
RESULTS
Breast-conservation therapy appears to be underused among African-American women, a pattern that is noted also among white women with breast carcinoma. Higher rates of locoregional recurrence are seen among African-American women regardless of whether they receive breast-conserving treatment or undergo mastectomy, and this appears to be a function of primary tumor biology. Response rates to appropriately delivered systemic therapy are similar for African-American patients and white patients.
CONCLUSIONS
Despite the apparent increased aggressiveness of disease seen in African-American women with breast carcinoma, patterns of response to local and systemic therapy are similar to the patterns seen in white women with breast carcinoma.
Topics: Black or African American; Breast Neoplasms; Delivery of Health Care; Female; Humans; Neoplasm Recurrence, Local; Treatment Outcome; United States
PubMed: 12491488
DOI: 10.1002/cncr.11015 -
Oncotarget Oct 2023Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single...
Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC). The preclinical efficacy of additional agents is also discussed, particularly the pan-HER inhibitor poziotinib.
Topics: Humans; Female; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Alleles; Receptor, ErbB-2
PubMed: 37921670
DOI: 10.18632/oncotarget.28489 -
International Journal of Molecular... Aug 2023The continuous evolution of cancer biology has led to the discovery of mammaglobin, a potential novel biomarker for breast carcinoma. This review aims to unravel the... (Review)
Review
The continuous evolution of cancer biology has led to the discovery of mammaglobin, a potential novel biomarker for breast carcinoma. This review aims to unravel the enigmatic aspects of mammaglobin and elucidate its potential role in redefining the paradigm of breast carcinoma biomarkers. We will thoroughly examine its expression in tumoral and peritumoral tissues and its circulating levels in the blood, thereby providing insights into its possible function in cancer progression and metastasis. Furthermore, the potential application of mammaglobin as a non-invasive diagnostic tool and a target for personalized treatment strategies will be discussed. Given the increasing incidence of breast carcinoma worldwide, the exploration of novel biomarkers such as mammaglobin is crucial in advancing our diagnostic capabilities and treatment modalities, ultimately contributing to improved patient outcomes.
Topics: Humans; Female; Breast Neoplasms; Biomarkers; Biology
PubMed: 37686210
DOI: 10.3390/ijms241713407 -
Medical Principles and Practice :... 2020An association of Epstein-Barr virus (EBV) infection with breast carcinoma (BC) risk has so far been disputed in the literature. Therefore, we performed a meta-analysis... (Meta-Analysis)
Meta-Analysis
OBJECTIVE
An association of Epstein-Barr virus (EBV) infection with breast carcinoma (BC) risk has so far been disputed in the literature. Therefore, we performed a meta-analysis to clarify this relationship.
MATERIALS AND METHODS
An electronic database search for eligible case-control studies was performed using PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data until May 17, 2018. The pooled OR and 95% CI were used to estimate the relationship between EBV infection and BC risk using a fixed or random-effects model depending on heterogeneity. Subgroup analysis and meta-regression were used to explore the heterogeneity. Publication bias was assessed using Egger's and Harbord's tests.
RESULTS
A total of 16 studies with 1,279 patients and 814 controls were reviewed based on our inclusion and exclusion criteria. Compared with the control group, EBV infection had a significant association with BC risk (OR 4.75, 95% CI 2.53-8.92, p < 0.01) with significant heterogeneity observed (I2 = 65.3%). The subgroup analysis revealed that region and tissue type might explain potential sources of heterogeneity. The sensitivity analyses yielded stable results. No significant publication bias was observed.
CONCLUSION
The current results suggest that EBV infection is significantly associated with increased risk of BC.
Topics: Breast Neoplasms; Carcinoma; Epstein-Barr Virus Infections; Female; Humans; Risk Factors
PubMed: 31311020
DOI: 10.1159/000502131 -
Clinical & Translational Oncology :... Nov 2020Apolipoproteins, the key components of lipoproteins, play vital roles in the combination and transportation of lipids. Numerous research articles have accumulated solid... (Review)
Review
Apolipoproteins, the key components of lipoproteins, play vital roles in the combination and transportation of lipids. Numerous research articles have accumulated solid evidence that lipoproteins are closely related to various types of tumorigenesis. In this review, we focused on the associations between several apolipoproteins and breast carcinoma and distinguished the effects and significance of apolipoproteins in different locations to validate their roles in breast carcinoma development. For example, apoD and apoE in serum are viewed as risk factors for breast carcinoma. ApoD, apoE and apoA-I in mammary tissues inhibit tumor growth. Moreover, apoB, apoJ and apoA-I have the potential to function as diagnostic or prognostic markers in the clinic. ApoEdp and apoJ treatment on breast carcinoma could significantly restrict tumor growth. In general, the aim of this review was to further analyze the associations between some members of the apolipoprotein family and breast cancer.
Topics: Apolipoproteins; Breast Neoplasms; Carrier Proteins; Female; Humans; Lipid Metabolism
PubMed: 32306242
DOI: 10.1007/s12094-020-02354-2